Aspect Biosystems Ltd., a leader in the field of 3D bioprinting and tissue engineering, announced today that it has entered into a research collaboration with DePuy Synthes Products Inc. Under the agreement, facilitated by Johnson & Johnson Innovation, Aspect’s proprietary Lab-on-a-Printer™ 3D bioprinting platform will be used to develop bioprinted knee meniscus tissue suitable for surgical therapy.
“We are very excited to work with a global healthcare leader like DePuy Synthes” said Tamer Mohamed, President and CEO of Aspect Biosystems. “This collaboration marks a significant step for Aspect to apply our 3D bioprinting platform technology in developing groundbreaking tissue replacement therapies that hold the real potential to improve quality of life for patients.”
About Aspect Biosystems Ltd.
Aspect Biosystems Ltd. is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. The company’s proprietary Lab-on-a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used to advance and accelerate the discovery and development of new drugs and therapies.